BioCentury
ARTICLE | Clinical News

MedImmune starts CAIV-T Phase III

October 20, 2004 7:00 AM UTC

MEDI began an international, double-blind Phase III trial of its CAIV-T second-generation intranasal influenza vaccine in 7,000 children between the ages of six and 59 months. The study is designed to compare the efficacy of CAIV-T with an injectable flu vaccine from Sanofi- Aventis (Euronext:SAN; SNY). CAIV-T is a next-generation, refrigerator-stable liquid formulation of FluMist, a frozen intranasal flu vaccine that MEDI markets for people aged five to 49.

In addition, MEDI completed enrollment of a U.S. bridging study in 977 patients aged five to 49 that is designed to demonstrate equivalency between CAIV-T and FluMist. The company expects results for both studies by the middle of next year and restated that it anticipates CAIV-T being approved for an expanded patient population in time for the 2007-08 flu season. ...